SILENCE THERAP. SP.ADR/1 (XRP2) — Net Asset Quality Index
SILENCE THERAP. SP.ADR/1 (XRP2) has a Net Asset Quality Index of 47.4% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €131.44 Million minus total liabilities of €69.14 Million yields net assets of €62.30 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read SILENCE THERAP. SP.ADR/1 total liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
SILENCE THERAP. SP.ADR/1 Net Asset Quality Index Over Time (2021–2025)
This chart shows how SILENCE THERAP. SP.ADR/1's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the index stands at 47.4%, representing net assets of €62.30 Million against total assets of €131.44 Million EUR. For live market cap and overall valuation, see how much is SILENCE THERAP. SP.ADR/1 worth.
Annual Net Asset Quality Index for SILENCE THERAP. SP.ADR/1 (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for SILENCE THERAP. SP.ADR/1 from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check SILENCE THERAP. SP.ADR/1 strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 47.4% | €62.30 Million | €131.44 Million | €69.14 Million | ▼ -18.7 pp |
| 2024 | 66.1% | €134.02 Million | €202.63 Million | €68.61 Million | ▲ +47.7 pp |
| 2023 | 18.4% | €21.99 Million | €119.45 Million | €97.45 Million | ▼ -2.1 pp |
| 2022 | 20.5% | €26.71 Million | €130.10 Million | €103.38 Million | ▲ +11.7 pp |
| 2021 | 8.9% | €11.51 Million | €129.83 Million | €118.32 Million | — |